TB/Non-TB Mycobacterial Infections
Systematic Review | Global frequency and clinical features of stroke in patients with tuberculous meningitis.
6 Sep, 2022 | 14:19h | UTC
RCT | Bedaquiline–Pretomanid–Linezolid regimens for drug-resistant tuberculosis.
2 Sep, 2022 | 13:16h | UTCBedaquiline–Pretomanid–Linezolid Regimens for Drug-Resistant Tuberculosis – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary: Three drug regimen with Linezolid 600 mg tied to better outcomes in drug-resistant TB – Medical Dialogues
Perspective | Ending tuberculosis in a post-COVID-19 world: a person-centered, equity-oriented approach.
19 Aug, 2022 | 16:02h | UTC
Commentary on Twitter
New personal view: Ending tuberculosis in a post-COVID-19 world: a person-centred, equity-oriented approach https://t.co/jLFPLWc39w pic.twitter.com/TBlSYlp4P0
— The Lancet Infectious Diseases (@TheLancetInfDis) August 11, 2022
Perspective | Epidemiological approach to ending tuberculosis in high-burden countries.
19 Aug, 2022 | 15:59h | UTCEpidemiological approach to ending tuberculosis in high-burden countries – The Lancet
Commentary on Twitter
"We need to make concerted efforts now to finally eliminate #tuberculosis everywhere."@Marks1Guy and colleagues on an epidemiological approach in high-burden countries: https://t.co/MXviPYdp2q pic.twitter.com/CXt1BOgQW8
— The Lancet (@TheLancet) August 6, 2022
M-A | Infant BCG vaccination and risk of pulmonary and extrapulmonary tuberculosis throughout the life course.
15 Aug, 2022 | 12:21h | UTCInvited Commentary: Infant BCG vaccination is beneficial, but not sufficient – The Lancet Global Health
News Release: BCG vaccine prevents tuberculosis in young children, but not adults – Boston University School of Public Health
Commentary from the author on Twitter (thread – click for more)
1/n Our new @LancetGH study investigating BCG vaccination in infancy and tuberculosis risk is out!
Link: https://t.co/Gu469QlnFh pic.twitter.com/yRIdb2I7Zr
— Leo Martinez (@LeoMarti_EpiTB) August 9, 2022
M-A | Global prevalence of non-tuberculous mycobacteria in adults with non-cystic fibrosis bronchiectasis 2006–2021.
3 Aug, 2022 | 14:04h | UTC
M-A | Lung cancer occurrence after an episode of tuberculosis.
29 Jul, 2022 | 12:28h | UTC
Review | Tuberculosis in cirrhosis – A diagnostic and management conundrum.
7 Jul, 2022 | 12:18h | UTC
M-A: Treatment outcomes among pregnant patients with multidrug-resistant tuberculosis.
15 Jun, 2022 | 10:47h | UTC
Commentary on Twitter
This meta-analysis of pregnant patients treated for multi-drug-resistant tuberculosis (MDR-TB) found 73% treatment success and 73% favorable pregnancy outcomes, with adverse events (incl liver/kidney impairment, hearing loss) in more than half of patients. https://t.co/Mx5RLiwhU9
— JAMA Network Open (@JAMANetworkOpen) June 10, 2022
Systematic Review: Xpert MTB/XDR for detection of pulmonary tuberculosis and resistance to isoniazid, fluoroquinolones, ethionamide, and amikacin.
25 May, 2022 | 10:46h | UTCSummary: Xpert MTB/XDR, a rapid test for resistance to tuberculosis drugs – Cochrane Library
Modeling Study: 20% of multi-drug resistant tuberculosis cases in children could be averted by household testing and treatment.
25 May, 2022 | 10:44h | UTCInvited Commentary: Investing in drug-resistant tuberculosis household contact management and preventive treatment – The Lancet Global Health
WHO calls for shorter drug course for resistant TB.
4 May, 2022 | 11:08h | UTCWHO calls for shorter drug course for resistant TB – CIDRAP
Rapid communication: Key changes to the treatment of drug-resistant tuberculosis – World Health Organization
Review: Anti-tuberculosis treatment strategies and drug development: challenges and priorities.
1 May, 2022 | 23:23h | UTCAnti-tuberculosis treatment strategies and drug development: challenges and priorities – Nature Reviews Microbiology (if the link is paywalled, try this one)
News Release: A major update on global tuberculosis fight – Hackensack Meridian Health
Commentary on Twitter
Anti-tuberculosis treatment strategies and drug development: challenges and prioritieshttps://t.co/nZlcEwTDLP
In this Review, Dartois and Rubin explore challenges and priorities for anti-tuberculosis treatment strategies and drug development.@vdartois1 pic.twitter.com/t6RQoaFb8C
— Nature Reviews Microbiology (@NatureRevMicro) April 27, 2022
Rapid molecular tests for tuberculosis and tuberculosis drug resistance: a qualitative evidence synthesis of recipient and provider views.
27 Apr, 2022 | 07:52h | UTC
Drug resistant TB – latest developments in epidemiology, diagnostics and management.
13 Apr, 2022 | 10:09h | UTCRelated:
Summary | WHO recommendations on the treatment of drug-resistant tuberculosis, 2020 update.
WHO Consolidated Guidelines on Drug-resistant Tuberculosis Treatment
Canadian Tuberculosis Standards – 8th Edition.
Guideline: Treatment of Drug-Resistant Tuberculosis
The Lancet Commission: Management of Multidrug-resistant and Incurable Tuberculosis
Regimens to Treat Multidrug-resistant Tuberculosis: Past, Present and Future Perspectives
Canadian Tuberculosis Standards – 8th Edition.
28 Mar, 2022 | 09:46h | UTCChapter 1: Epidemiology of tuberculosis in Canada
Chapter 2: Transmission and pathogenesis of tuberculosis
Chapter 3: Diagnosis of tuberculosis disease and drug-resistant tuberculosis
Chapter 4: Diagnosis of tuberculosis infection
Chapter 5: Treatment of tuberculosis disease
Chapter 6: Tuberculosis preventive treatment in adults
Chapter 7: Extra-pulmonary tuberculosis
Chapter 8: Drug-resistant tuberculosis
Chapter 9: Pediatric tuberculosis
Chapter 10: Treatment of active tuberculosis in special populations
Chapter 11: Tuberculosis contact investigation and outbreak management
Chapter 13: Tuberculosis surveillance and tuberculosis infection testing and treatment in migrants
Chapter 14: Prevention and control of tuberculosis transmission in healthcare settings
Chapter 15: Monitoring tuberculosis program performance
Systematic Review: Symptom‐ and chest‐radiography screening for active pulmonary tuberculosis in HIV‐negative adults and adults with unknown HIV status.
28 Mar, 2022 | 08:54h | UTC
Cochrane Special Collection: Diagnosing tuberculosis.
25 Mar, 2022 | 09:57h | UTCDiagnosing tuberculosis – Cochrane Library
M-A: Tuberculosis screening among HIV-positive inpatients.
25 Mar, 2022 | 08:35h | UTC
Commentary on Twitter
Tuberculosis screening among HIV-positive inpatients: a systematic review and individual participant data meta-analysis https://t.co/DqTUr2JxHy In setting where TB prevalence is > 10%, WHO now strongly recommends molecular rapid diagnostic testing in all medical inpatient PWH.
— Carlos del Rio (@CarlosdelRio7) March 24, 2022
RCT: High dose Rifampicin with or without Levofloxacin vs. standard of care for pediatric tuberculous meningitis.
24 Mar, 2022 | 08:12h | UTC
New WHO guidelines on the management of tuberculosis in children and adolescents.
22 Mar, 2022 | 09:52h | UTC
A validated score for evaluating spinal instability to assess surgical candidacy in active spinal tuberculosis—an evidence based approach and multinational expert consensus study.
21 Mar, 2022 | 08:21h | UTC
Cohort Study: TNF inhibitors increase the risk of nontuberculous mycobacteria in patients with seropositive rheumatoid arthritis in a mycobacterium tuberculosis endemic area.
16 Mar, 2022 | 08:44h | UTC
Review: Mycobacterial skin infection.
14 Mar, 2022 | 00:59h | UTCMycobacterial skin infection – Current Opinion in Infectious Diseases
RCT: In children with nonsevere, drug-susceptible tuberculosis, treatment for 4 months is noninferior to treatment for 6 months.
10 Mar, 2022 | 11:03h | UTCNews Release: Treatment length reduced for children with tuberculosis – University College London
Commentary on Twitter
Completing 6 months of treatment for tuberculosis in children is a challenge. In this open-label trial involving 1204 children in sub-Saharan Africa and India, 4 months of antituberculosis therapy was noninferior to 6 months of therapy. https://t.co/zkD4URWMru pic.twitter.com/LFR6ZzTKgs
— NEJM (@NEJM) March 9, 2022